Heron Therapeutics (HRTX) : The short interest in Heron Therapeutics (HRTX) has increased from 9,390,797 to 11,110,892 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 1,583,091 shares are traded daily in the stock and only 7 days are left for the shorts to cover. The short open interest is 30.7% of the total shares in the hands of the public. The shorts in the stock have gone up by 1,720,095 shares, which is an increase of 18.3% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.
Heron Therapeutics (NASDAQ:HRTX): The stock opened at $20.91 on Wednesday but the bulls could not build on the opening and the stock topped out at $21.24 for the day. The stock traded down to $19.74 during the day, due to lack of any buying support eventually closed down at $19.85 with a loss of -4.93% for the day. The stock had closed at $20.88 on the previous day. The total traded volume was 886,860 shares.
In a related news, The Securities and Exchange Commission has divulged that Rosen Robert, director officer (President & CCO) of Heron Therapeutics, Inc. /De/, had unloaded 100,000 shares at an average price of $23.55 in a transaction dated on August 10, 2016. The total value of the transaction was worth $2,355,000.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Companys product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Companys product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Companys other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.